Preservation and Expansion of Current Domestic Capacities for Laboratory-Based Testing and Manufacturing of Over-The-Counter (OTC) Rapid Antigen and Point-Of-Care (POC) Nucleic Acid Amplification Tests (NAATs)

The COVID-19 pandemic has demonstrated how important a robust and resilient public health industrial base is in ensuring the health and security of the United States. It also highlighted the need for critical public health industrial investments at a scale never seen before in the United States. The HHS is conducting market research from manufacturers on their expertise, capacities, challenges, and innovative best practices with various components of the supply chain. Please refer to the attachment for further information.